Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
27 May 2021 - 6:59AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16 of
the Securities Exchange Act of 1934
For the month of May 2021
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245
Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44
(0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal
Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Notice of Annual General Meeting
On May 26, 2021, Achilles Therapeutics plc (Achilles or the Company) issued notice of the Companys Annual
General Meeting, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 6-K. The Companys Annual General Meeting will be held at 245 Hammersmith Road, London W6 8PW, United Kingdom
on June 28, 2021 at 17:00 (UK time). Furnished (i) as Exhibit 99.2 to this Current Report on Form 6-K is the Form of Proxy for the Bank of New York Mellon (the Depositary), (ii) as
Exhibit 99.3 to this Current Report on Form 6-K is the Voting Instruction Form for holders of American Depositary Shares and (iii) as Exhibit 99.4 to this Current Report on Form 6-K are the Voting Instructions for holders of American Depositary Shares.
The statements contained in
this Notice of Annual General Meeting section of this Current Report on Form 6-K and the information contained in Exhibits 99.1, 99.2, 99.3 and 99.4 shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and are not incorporated by reference into any of the Companys filings under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLES THERAPEUTICS PLC
|
|
|
|
|
Date: May 26, 2021
|
|
|
|
By:
|
|
/s/ Robert Coutts
|
|
|
|
|
|
|
Robert Coutts
|
|
|
|
|
|
|
Chief Financial Officer
|
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Aug 2023 to Aug 2024